This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schwaber, M. J.
Right arrow Articles by Carmeli, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwaber, M. J.
Right arrow Articles by Carmeli, Y.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2005, p. 2137-2139, Vol. 49, No. 5
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.5.2137-2139.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

High Levels of Antimicrobial Coresistance among Extended-Spectrum-ß-Lactamase-Producing Enterobacteriaceae

Mitchell J. Schwaber,1* Shiri Navon-Venezia,1 David Schwartz,2 and Yehuda Carmeli1

Division of Epidemiology,1 Laboratory of Clinical Microbiology, Tel Aviv Sourasky Medical Center, 6 Weizmann St., Tel Aviv 64239, Israel2

Received 22 November 2004/ Returned for modification 13 December 2004/ Accepted 3 January 2005


arrow
ABSTRACT
 
We compared the susceptibility of 312 extended-spectrum ß-lactamase (ESBL)-producing Enterobacteriaceae isolates with that of 1,216 ESBL nonproducers. Of ESBL producers, 25% were susceptible to gentamicin, 30% to trimethoprim-sulfamethoxazole, 41% to ciprofloxacin, and 60% to piperacillin-tazobactam. ESBL nonproducers were more often susceptible to these agents. ESBL-producing Enterobacteriaceae represent a major source of resistance to various antibiotics.


arrow
TEXT
 
The production of extended-spectrum ß-lactamases (ESBLs) by gram-negative bacteria renders ineffective all penicillins, cephalosporins, and aztreonam in the treatment of serious infections caused by these pathogens (9). Moreover, the phenomenon of antimicrobial coresistance among certain ESBL-producing isolates has been reported, further curtailing the number of drugs useful against these bacteria (1, 11, 12, 16). The literature lacks, however, a comprehensive report of resistance encompassing the Enterobacteriaceae and all potentially useful non-ß-lactam antimicrobial agents for both ESBL producers and nonproducers.

At our institution, a 1,200-bed urban teaching hospital, 20% of all bloodstream isolates of Enterobacteriaceae produce ESBLs. This high prevalence must be taken into account when devising empirical treatment regimens for suspected gram-negative infection before culture and susceptibility data are available. Moreover, we know that among the four most common Enterobacteriaceae isolated at our institution, approximately 40% are resistant to trimethoprim-sulfamethoxazole, 30% to ciprofloxacin, 30% to gentamicin, and 15% to piperacillin-tazobactam, while only 1% are resistant to amikacin. We suspected that these high levels of resistance to non-ß-lactams are associated with ESBL presence.

We compared antimicrobial coresistance between ESBL-producing and ESBL-nonproducing Enterobacteriaceae to determine the impact of ESBL presence on the likelihood of resistance to antimicrobial classes in addition to ß-lactams. We selected cefuroxime-resistant strains of Enterobacteriaceae isolated in the clinical microbiology laboratory from 2000 through 2003 for ESBL testing (8). Two control groups of ESBL nonproducers were assembled from the pool of cefuroxime-resistant (CXM-R) and cefuroxime-nonresistant (CXM-NR) Enterobacteriaceae isolates grown in the microbiology laboratory during the same time period. Urinary isolates were excluded from the study, as NCCLS guidelines for ESBL testing apply to these on an institutional basis only (9). Duplicate isolates from the same patient were excluded.

Confirmatory testing for ESBL presence was performed by disk diffusion using ceftazidime- and cefotaxime-impregnated disks, with and without clavulanic acid (CA) (9). Isolates demonstrating a CA effect, defined as an increase in zone diameter of ≥5 mm in the presence of CA for at least one antibiotic, were considered to be ESBL producers (9).

Antimicrobial susceptibilities were performed using the VITEK 2 system (bioMérieux, Durham, NC) and interpreted according to NCCLS guidelines. Drugs tested were ciprofloxacin, gentamicin, amikacin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem. Organisms intermediately susceptible to a given agent were deemed resistant. The proportion of isolates susceptible to each agent was compared for cases and controls.

Three hundred twelve ESBL producers were surveyed, alongside 929 CXM-NR controls and 287 CXM-R controls. Samples comprised eight different genera. Twelve ESBL producers were resistant to all five antimicrobials tested, while 70 were resistant to four of the agents.

High levels of coresistance (≥40%) were noted among the cases for all agents except amikacin and imipenem. The CXM-NR controls, by contrast, demonstrated ≥89% susceptibility to all agents except trimethoprim-sulfamethoxazole, and still a greater percentage of controls than cases was susceptible to this agent as well (77% versus 30%, P < 0.001 by chi square). Among CXM-R controls, 59% were susceptible to trimethoprim-sulfamethoxazole and ≥65% were susceptible to each of the other agents tested. The results of the case-control comparison are displayed in Table 1. Figure 1 illustrates the burden of resistance to each agent attributable to ESBL presence in each of the four most common Enterobacteriaceae isolated. As is evident, ESBL producers comprise a large proportion of isolates resistant to various antibiotic classes.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Proportions of isolates susceptible to the antimicrobial agents examineda



View larger version (52K):
[in this window]
[in a new window]
  		FIG. 1. The burden of antimicrobial resistance attributable to ESBL producers. The bars represent the percentages of ESBL producers among resistant isolates of the four most common Enterobacteriaceae found at our institution, for four agents with activity against gram-negative pathogens. TZP, piperacillin-tazobactam; GM, gentamicin; CIP, ciprofloxacin; SXT, trimethoprim-sulfamethoxazole.

In the two decades since ESBLs were first detected, these enzymes have emerged as a major source of antimicrobial resistance among healthcare-associated gram-negative pathogens (16) and are reported in many parts of the world (1, 11, 12, 16). Infection with ESBL-producing pathogens generally necessitates the use of non-ß-lactam antibiotics. Data from several studies have suggested that ESBL presence may be associated with resistance to antimicrobial classes other than ß-lactams as well, rendering treatment even more difficult (1, 11, 12, 16).

As resistance plasmids are the major source of ESBL transmission (4), and we have determined that the ESBL-producing isolates of common species of Enterobacteriaceae in our institution comprise multiple genotypes (13; unpublished data), we postulate that transferable elements conferring resistance to antimicrobials other than ß-lactams travel on or alongside the ESBL-containing plasmids, yielding multidrug-resistant bacteria. Numerous mechanisms exist for resistance to the antimicrobial classes described, and in each case a plasmid-mediated resistance mechanism has been described (6, 7, 10, 15, 17). It is also possible that mechanisms other than, or in addition to, plasmid-mediated cotransfer of various resistance factors account for the phenomenon of coresistance observed (2, 5, 17).

Our findings are worrisome for several reasons. First, our institution has a higher prevalence of ESBLs among isolates of Enterobacteriaceae than that reported in numerous surveys spanning several geographic regions (3, 11, 14, 16). Second, the levels of coresistance among the ESBL isolates are appreciably higher for all antimicrobials tested except amikacin and imipenem, the only two agents with generally adequate coverage of ESBL-producing Enterobacteriaceae. The clinical implications of our findings are that when infection with an ESBL-producing organism is considered a reasonable possibility, appropriate empirical coverage may necessitate some form of combination therapy involving suboptimal agents or may be limited to the carbapenems and amikacin. The dearth of new broad-spectrum antimicrobial agents with activity against gram-negative pathogens further adds to the bleakness of our findings.

The silver lining to our results is the fact that almost all cefuroxime-nonresistant controls, and even the majority of cefuroxime-resistant controls, remained susceptible to all appropriate antimicrobial classes, leaving a broad range of possibilities for effective treatment of infections with these non-ESBL-producing pathogens. If we can bring about a decrease in the prevalence of ESBL producers, the possibilities for empirical coverage of infection with Enterobacteriaceae should become much broader. Thus, if we can control the spread of ESBLs, we can significantly curtail the problem of antimicrobial resistance among nosocomial Enterobacteriaceae isolates. The bleak susceptibility profile offered by the ESBL producers, along with the wide range of treatment options offered by the nonproducers, suggest that appropriate infection control measures aimed at minimizing the spread of ESBLs should be a high priority.


arrow
ACKNOWLEDGMENTS
 
This work was supported in part by a grant from the Israel-United States Binational Science Foundation.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Division of Epidemiology, Tel Aviv Sourasky Medical Center, 6 Weizmann St., Tel Aviv 64239, Israel. Phone: 972-52-426-6800. Fax: 972-3-697-3256. E-mail: schwm{at}massmed.org. Back


arrow
REFERENCES
 
    1
  1. Bell, J. M., J. D. Turnidge, A. C. Gales, M. A. Pfaller, and R. N. Jones. 2002. Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagn. Microbiol. Infect. Dis. 42:193-198.[CrossRef][Medline]
    2. 2
  2. Chopra, I., A. J. O'Neill, and K. Miller. 2003. The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist. Updates 6:137-145.[CrossRef][Medline]
    3. 3
  3. Einhorn, A. E., M. M. Neuhauser, D. T. Bearden, J. P. Quinn, and S. L. Pendland. 2002. Extended-spectrum beta-lactamases: frequency, risk factors, and outcomes. Pharmacotherapy 22:14-20.[CrossRef][Medline]
    4. 4
  4. Fierer, J., and D. Guiney. 1999. Extended-spectrum beta-lactamases: a plague of plasmids. JAMA 281:563-564.[Free Full Text]
    5. 5
  5. Gruteke, P., W. Goessens, J. van Gils, P. Peerbooms, N. Lemmens-den Toom, M. van Santen-Verheuvel, A. van Belkum, and H. Verbrugh. 2003. Patterns of resistance associated with integrons, the extended-spectrum ß-lactamase SHV-5 gene, and a multidrug efflux pump of Klebsiella pneumoniae causing a nosocomial outbreak. J. Clin. Microbiol. 41:1161-1166.[Abstract/Free Full Text]
    6. 6
  6. Jacoby, G. A., N. Chow, and K. B. Waites. 2003. Prevalence of plasmid-mediated quinolone resistance. Antimicrob. Agents Chemother. 47:559-562.[Abstract/Free Full Text]
    7. 7
  7. Kaye, K. S., H. S. Gold, M. J. Schwaber, L. Venkataraman, Y. Qi, P. C. De Girolami, M. H. Samore, G. Anderson, J. K. Rasheed, and F. C. Tenover. 2004. Variety of ß-lactamases produced by amoxicillin-clavulanate-resistant Escherichia coli isolated in the northeastern United States. Antimicrob. Agents Chemother. 48:1520-1525.[Abstract/Free Full Text]
    8. 8
  8. Navon-Venezia, S., O. Hammer-Münz, D. Schwartz, D. Turner, B. Kuzmenko, and Y. Carmeli. 2003. Occurrence and phenotypic characteristics of extended-spectrum ß-lactamases among members of the family Enterobacteriaceae at the Tel-Aviv Medical Center (Israel) and evaluation of diagnostic tests. J. Clin. Microbiol. 41:155-158.[Abstract/Free Full Text]
    9. 9
  9. National Committee for Clinical Laboratory Standards. 2004. Performance standards for antimicrobial susceptibility testing; fourteenth informational supplement. M100-S14, p. 24, Table 2A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    10. 10
  10. Opal, S. M., K. H. Mayer, and A. A. Medeiros. 2000. Mechanisms of bacterial resistance, p. 236-258. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 5th edition. Churchill Livingstone, Philadelphia, Pa.
    11. 11
  11. Oteo, J., J. Campos, and F. Baquero. 2002. Antibiotic resistance in 1962 invasive isolates of Escherichia coli in 27 Spanish hospitals participating in the European Antimicrobial Resistance Surveillance System (2001). J. Antimicrob. Chemother. 50:945-952.[Abstract/Free Full Text]
    12. 12
  12. Paterson, D. L., L. Mulazimoglu, J. M. Casellas, W. C. Ko, H. Goossens, A. Von Gottberg, S. Mohapatra, G. M. Trenholme, K. P. Klugman, J. G. McCormack, and V. L. Yu. 2000. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin. Infect. Dis. 30:473-478.[CrossRef][Medline]
    13. 13
  13. Schlesinger, J., S. Navon-Venezia, I. Chmelnitzky, O. Hammer-Münz, A. Leavitt, H. S. Gold, M. J. Schwaber, and Y. Carmeli. 2005. Extended-spectrum beta-lactamases among Enterobacter isolates in Tel Aviv, Israel. Antimicrob. Agents Chemother. 49:1150-1156.[Abstract/Free Full Text]
    14. 14
  14. Schwaber, M. J., P. M. Raney, J. K. Rasheed, J. W. Biddle, P. Williams, J. E. McGowan, Jr., and F. C. Tenover. 2004. Utility of NCCLS guidelines for identifying extended-spectrum ß-lactamases in non-Escherichia coli and non-Klebsiella spp. of Enterobacteriaceae. J. Clin. Microbiol. 42:294-298.[Abstract/Free Full Text]
    15. 15
  15. Shimizu, K., T. Kumada, W.-C. Hsieh, H.-Y. Chung, Y. Chong, R. S. Hare, G. H. Miller, F. J. Sabatelli, and J. Howard. 1985. Comparison of aminoglycoside resistance patterns in Japan, Formosa, and Korea, Chile, and the United States. Antimicrob. Agents Chemother. 28:282-288.[Abstract/Free Full Text]
    16. 16
  16. Spanu, T., F. Luzzaro, M. Perilli, G. Amicosante, A. Toniolo, G. Fadda, and The Italian ESBL Study Group. 2002. Occurrence of extended-spectrum ß-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to ß-lactams and other antimicrobial drugs. Antimicrob. Agents Chemother. 46:196-202.[Abstract/Free Full Text]
    17. 17
  17. Wang, M., D. F. Sahm, G. A. Jacoby, and D. C. Hooper. 2004. Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob. Agents Chemother. 48:1295-1299.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, May 2005, p. 2137-2139, Vol. 49, No. 5
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.5.2137-2139.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Baughman, R. P. (2009). The Use of Carbapenems in the Treatment of Serious Infections. J Intensive Care Med 24: 230-241 [Abstract]  
  • Leavitt, A., Chmelnitsky, I., Colodner, R., Ofek, I., Carmeli, Y., Navon-Venezia, S. (2009). Ertapenem Resistance among Extended-Spectrum-{beta}-Lactamase-Producing Klebsiella pneumoniae Isolates. J. Clin. Microbiol. 47: 969-974 [Abstract] [Full Text]  
  • Wright, B. M., Eiland, E. H. III (2008). Current Perspectives on Extended-Spectrum Beta-Lactamase-Producing Gram-Negative Bacilli. Journal of Pharmacy Practice 21: 338-345 [Abstract]  
  • Tumbarello, M., Sali, M., Trecarichi, E. M., Leone, F., Rossi, M., Fiori, B., De Pascale, G., D'Inzeo, T., Sanguinetti, M., Fadda, G., Cauda, R., Spanu, T. (2008). Bloodstream Infections Caused by Extended-Spectrum-{beta}-Lactamase- Producing Escherichia coli: Risk Factors for Inadequate Initial Antimicrobial Therapy. Antimicrob. Agents Chemother. 52: 3244-3252 [Abstract] [Full Text]  
  • Giske, C. G., Monnet, D. L., Cars, O., Carmeli, Y., on behalf of ReAct-Action on Antibiotic Resistance, (2008). Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli. Antimicrob. Agents Chemother. 52: 813-821 [Full Text]  
  • Schwaber, M. J., Carmeli, Y. (2007). Mortality and delay in effective therapy associated with extended-spectrum {beta}-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 60: 913-920 [Abstract] [Full Text]  
  • Strahilevitz, J., Engelstein, D., Adler, A., Temper, V., Moses, A. E., Block, C., Robicsek, A. (2007). Changes in qnr Prevalence and Fluoroquinolone Resistance in Clinical Isolates of Klebsiella pneumoniae and Enterobacter spp. Collected from 1990 to 2005. Antimicrob. Agents Chemother. 51: 3001-3003 [Abstract] [Full Text]  
  • Tumbarello, M., Sanguinetti, M., Montuori, E., Trecarichi, E. M., Posteraro, B., Fiori, B., Citton, R., D'Inzeo, T., Fadda, G., Cauda, R., Spanu, T. (2007). Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum-{beta}-Lactamase-Producing Enterobacteriaceae: Importance of Inadequate Initial Antimicrobial Treatment. Antimicrob. Agents Chemother. 51: 1987-1994 [Abstract] [Full Text]  
  • Zimhony, O., Chmelnitsky, I., Bardenstein, R., Goland, S., Hammer Muntz, O., Navon Venezia, S., Carmeli, Y. (2006). Endocarditis Caused by Extended-Spectrum-{beta}-Lactamase-Producing Klebsiella pneumoniae: Emergence of Resistance to Ciprofloxacin and Piperacillin-Tazobactam during Treatment despite Initial Susceptibility.. Antimicrob. Agents Chemother. 50: 3179-3182 [Abstract] [Full Text]  
  • Morosini, M.-I., Garcia-Castillo, M., Coque, T. M., Valverde, A., Novais, A., Loza, E., Baquero, F., Canton, R. (2006). Antibiotic Coresistance in Extended-Spectrum-{beta}-Lactamase-Producing Enterobacteriaceae and In Vitro Activity of Tigecycline.. Antimicrob. Agents Chemother. 50: 2695-2699 [Abstract] [Full Text]  
  • Luzzaro, F., Mezzatesta, M., Mugnaioli, C., Perilli, M., Stefani, S., Amicosante, G., Rossolini, G. M., Toniolo, A. (2006). Trends in Production of Extended-Spectrum {beta}-Lactamases among Enterobacteria of Medical Interest: Report of the Second Italian Nationwide Survey.. J. Clin. Microbiol. 44: 1659-1664 [Abstract] [Full Text]  
  • Schwaber, M. J., Navon-Venezia, S., Kaye, K. S., Ben-Ami, R., Schwartz, D., Carmeli, Y. (2006). Clinical and Economic Impact of Bacteremia with Extended- Spectrum-{beta}-Lactamase-Producing Enterobacteriaceae.. Antimicrob. Agents Chemother. 50: 1257-1262 [Abstract] [Full Text]  
  • de Cueto, M., Lopez, L., Hernandez, J. R., Morillo, C., Pascual, A. (2006). In Vitro Activity of Fosfomycin against Extended-Spectrum-{beta}-Lactamase- Producing Escherichia coli and Klebsiella pneumoniae: Comparison of Susceptibility Testing Procedures. Antimicrob. Agents Chemother. 50: 368-370 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schwaber, M. J.
Right arrow Articles by Carmeli, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwaber, M. J.
Right arrow Articles by Carmeli, Y.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»